Immunome (IMNM) Equity Ratio (2023 - 2025)
Historic Equity Ratio for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to 0.88.
- Immunome's Equity Ratio rose 538.15% to 0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88, marking a year-over-year increase of 538.15%. This contributed to the annual value of 0.75 for FY2024, which is 656.35% down from last year.
- Immunome's Equity Ratio amounted to 0.88 in Q3 2025, which was up 538.15% from 0.91 recorded in Q2 2025.
- In the past 5 years, Immunome's Equity Ratio registered a high of 0.91 during Q2 2025, and its lowest value of 0.07 during Q3 2023.
- Over the past 3 years, Immunome's median Equity Ratio value was 0.84 (recorded in 2024), while the average stood at 0.67.
- Examining YoY changes over the last 5 years, Immunome's Equity Ratio showed a top increase of 118263.83% in 2024 and a maximum decrease of 656.35% in 2024.
- Quarter analysis of 3 years shows Immunome's Equity Ratio stood at 0.81 in 2023, then decreased by 6.56% to 0.75 in 2024, then grew by 16.9% to 0.88 in 2025.
- Its last three reported values are 0.88 in Q3 2025, 0.91 for Q2 2025, and 0.9 during Q1 2025.